1
|
Bayona C, Alza L, Ranđelović T, Sallán MC, Visa A, Cantí C, Ochoa I, Oliván S, Herreros J. Tetralol derivative NNC-55-0396 targets hypoxic cells in the glioblastoma microenvironment: an organ-on-chip approach. Cell Death Dis 2024; 15:127. [PMID: 38341408 PMCID: PMC10858941 DOI: 10.1038/s41419-024-06492-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 01/19/2024] [Accepted: 01/23/2024] [Indexed: 02/12/2024]
Abstract
Glioblastoma (GBM) is a highly malignant brain tumour characterised by limited treatment options and poor prognosis. The tumour microenvironment, particularly the central hypoxic region of the tumour, is known to play a pivotal role in GBM progression. Cells within this region adapt to hypoxia by stabilising transcription factor HIF1-α, which promotes cell proliferation, dedifferentiation and chemoresistance. In this study we sought to examine the effects of NNC-55-0396, a tetralol compound which overactivates the unfolded protein response inducing apoptosis, using the organ-on-chip technology. We identified an increased sensitivity of the hypoxic core of the chip to NNC, which correlates with decreasing levels of HIF1-α in vitro. Moreover, NNC blocks the macroautophagic process that is unleashed by hypoxia as revealed by increased levels of autophagosomal constituent LC3-II and autophagy chaperone p62/SQSTM1. The specific effects of NNC in the hypoxic microenvironment unveil additional anti-cancer abilities of this compound and further support investigations on its use in combined therapies against GBM.
Collapse
Affiliation(s)
- Clara Bayona
- Tissue Microenvironment (TME) Lab, Institute for Health Research Aragón (IIS Aragón), Aragón Institute of Engineering Research (I3A), University of Zaragoza, 50018, Zaragoza, Spain
| | - Lía Alza
- Calcium Cell Signaling, IRBLleida, University of Lleida, Rovira Roure 80, 25198, Lleida, Spain
| | - Teodora Ranđelović
- Tissue Microenvironment (TME) Lab, Institute for Health Research Aragón (IIS Aragón), Aragón Institute of Engineering Research (I3A), University of Zaragoza, 50018, Zaragoza, Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 50018, Zaragoza, Spain
| | - Marta C Sallán
- Calcium Cell Signaling, IRBLleida, University of Lleida, Rovira Roure 80, 25198, Lleida, Spain
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Anna Visa
- Calcium Cell Signaling, IRBLleida, University of Lleida, Rovira Roure 80, 25198, Lleida, Spain
| | - Carles Cantí
- Calcium Cell Signaling, IRBLleida, University of Lleida, Rovira Roure 80, 25198, Lleida, Spain
| | - Ignacio Ochoa
- Tissue Microenvironment (TME) Lab, Institute for Health Research Aragón (IIS Aragón), Aragón Institute of Engineering Research (I3A), University of Zaragoza, 50018, Zaragoza, Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 50018, Zaragoza, Spain
| | - Sara Oliván
- Tissue Microenvironment (TME) Lab, Institute for Health Research Aragón (IIS Aragón), Aragón Institute of Engineering Research (I3A), University of Zaragoza, 50018, Zaragoza, Spain.
| | - Judit Herreros
- Calcium Cell Signaling, IRBLleida, University of Lleida, Rovira Roure 80, 25198, Lleida, Spain.
| |
Collapse
|
2
|
Visa A, Sallán MC, Maiques O, Alza L, Talavera E, López-Ortega R, Santacana M, Herreros J, Cantí C. T-Type Ca v3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma. Cancer Res 2019; 79:1857-1868. [PMID: 30755443 DOI: 10.1158/0008-5472.can-18-1924] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2018] [Revised: 12/12/2018] [Accepted: 02/07/2019] [Indexed: 11/16/2022]
Abstract
T-type Ca2+ channels (TTCC) have been identified as key regulators of cancer cell cycle and survival. In vivo studies in glioblastoma (GBM) murine xenografts have shown that drugs able to block TTCC in vitro (such as tetralol derivatives mibefradil/NNC-55-096, or different 3,4-dihydroquinazolines) slow tumor progression. However, currently available TTCC pharmacologic blockers have limited selectivity for TTCC and are unable to distinguish between TTCC isoforms. Here we analyzed the expression of TTCC transcripts in human GBM cells and show a prevalence of Cacna1g/Cav3.1 mRNAs. Infection of GBM cells with lentiviral particles carrying short hairpin RNA against Cav3.1 resulted in GBM cell death by apoptosis. We generated a murine GBM xenograft via subcutaneous injection of U87-MG GBM cells and found that tumor size was reduced when Cav3.1 expression was silenced. Furthermore, we developed an in vitro model of temozolomide-resistant GBM that showed increased expression of Cav3.1 accompanied by the activation of macroautophagy. We confirmed a positive correlation between Cav3.1 and autophagic markers in both GBM cultures and biopsies. Of note, Cav3.1 knockdown resulted in transcriptional downregulation of p62/SQSTM1 and deficient autophagy. Together, these data identify Cav3.1 channels as potential targets for slowing GBM progression and recurrence based on their role in regulating autophagy. SIGNIFICANCE: These findings identify Cav3.1 calcium channels as a molecular target to regulate autophagy and prevent progression and chemotherapeutic resistance in glioblastoma.
Collapse
Affiliation(s)
- Anna Visa
- Calcium Signalling Lab, IRBLleida, University of Lleida, Lleida, Spain
| | - Marta C Sallán
- Calcium Signalling Lab, IRBLleida, University of Lleida, Lleida, Spain
| | - Oscar Maiques
- Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - Lía Alza
- Calcium Signalling Lab, IRBLleida, University of Lleida, Lleida, Spain
| | - Elisabet Talavera
- Cytogenetic Unit, Clinic Lab, Hospital Universitari Arnau de Vilanova, ICS, Lleida, Spain
| | - Ricard López-Ortega
- Cytogenetic Unit, Clinic Lab, Hospital Universitari Arnau de Vilanova, ICS, Lleida, Spain
| | | | - Judit Herreros
- Calcium Signalling Lab, IRBLleida, University of Lleida, Lleida, Spain.
| | - Carles Cantí
- Calcium Signalling Lab, IRBLleida, University of Lleida, Lleida, Spain.
| |
Collapse
|
3
|
Nàger M, Sallán MC, Visa A, Pushparaj C, Santacana M, Macià A, Yeramian A, Cantí C, Herreros J. Inhibition of WNT-CTNNB1 signaling upregulates SQSTM1 and sensitizes glioblastoma cells to autophagy blockers. Autophagy 2018; 14:619-636. [PMID: 29313411 DOI: 10.1080/15548627.2017.1423439] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
WNT-CTNN1B signaling promotes cancer cell proliferation and stemness. Furthermore, recent evidence indicates that macroautophagy/autophagy regulates WNT signaling. Here we investigated the impact of inhibiting WNT signaling on autophagy in glioblastoma (GBM), a devastating brain tumor. Inhibiting TCF, or silencing TCF4 or CTNNB1/β-catenin upregulated SQSTM1/p62 in GBM at transcriptional and protein levels and, in turn, autophagy. DKK1/Dickkopf1, a canonical WNT receptor antagonist, also induced autophagic flux. Importantly, TCF inhibition regulated autophagy through MTOR inhibition and dephosphorylation, and nuclear translocation of TFEB, a master regulator of lysosomal biogenesis and autophagy. TCF inhibition or silencing additionally affected GBM cell proliferation and migration. Autophagy induction followed by its blockade can promote cancer cell death. In agreement with this notion, halting both TCF-CTNNB1 and autophagy pathways decreased cell viability and induced apoptosis of GBM cells through a SQSTM1-dependent mechanism involving CASP8 (caspase 8). In vivo experiments further underline the therapeutic potential of such dual targeting in GBM.
Collapse
Affiliation(s)
- Mireia Nàger
- a Department of Basic Medical Sciences , University of Lleida, IRBLleida , Lleida , Spain
| | - Marta C Sallán
- b Department of Experimental Medicine , University of Lleida, IRBLleida , Lleida , Spain
| | - Anna Visa
- b Department of Experimental Medicine , University of Lleida, IRBLleida , Lleida , Spain
| | - Charumathi Pushparaj
- b Department of Experimental Medicine , University of Lleida, IRBLleida , Lleida , Spain
| | | | - Anna Macià
- b Department of Experimental Medicine , University of Lleida, IRBLleida , Lleida , Spain
| | - Andrée Yeramian
- a Department of Basic Medical Sciences , University of Lleida, IRBLleida , Lleida , Spain
| | - Carles Cantí
- b Department of Experimental Medicine , University of Lleida, IRBLleida , Lleida , Spain
| | - Judit Herreros
- a Department of Basic Medical Sciences , University of Lleida, IRBLleida , Lleida , Spain
| |
Collapse
|
4
|
Bhardwaj D, Náger M, Visa A, Sallán MC, Coopman PJ, Cantí C, Herreros J. Phosphorylated Tyr142 β‐catenin localizes to centrosomes and is regulated by Syk. J Cell Biochem 2018; 119:3632-3640. [DOI: 10.1002/jcb.26571] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Accepted: 11/28/2017] [Indexed: 11/06/2022]
Affiliation(s)
- Deepshikha Bhardwaj
- Department of Basic Medical SciencesUniversity of Lleida. IRBLleidaLleidaSpain
| | - Mireia Náger
- Department of Basic Medical SciencesUniversity of Lleida. IRBLleidaLleidaSpain
| | - Anna Visa
- Department of Experimental MedicineUniversity of Lleida. IRBLleidaLleidaSpain
| | - Marta C. Sallán
- Department of Experimental MedicineUniversity of Lleida. IRBLleidaLleidaSpain
| | - Peter J. Coopman
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194Université Montpellier, ICM, CNRSMontpellierFrance
| | - Carles Cantí
- Department of Experimental MedicineUniversity of Lleida. IRBLleidaLleidaSpain
| | - Judit Herreros
- Department of Basic Medical SciencesUniversity of Lleida. IRBLleidaLleidaSpain
| |
Collapse
|